CASI ap­points new pres­i­dent for China Op­er­a­tions

BioSpectrum (Asia) - - PEOPLE NEWS -

CASI Phar­ma­ceu­ti­cals, a bio­phar­ma­ceu­ti­cal com­pany ded­i­cated to the de­vel­op­ment and de­liv­ery of high qual­ity, cost­ef­fec­tive phar­ma­ceu­ti­cal prod­ucts and in­no­va­tive ther­a­peu­tics to pa­tients in the U.S., China and through­out the world, has an­nounced the ap­point­ment of Larry Zhang to the po­si­tion of Pres­i­dent of CASI (Bei­jing) Phar­ma­ceu­ti­cals Co., Ltd., the China op­er­at­ing sub­sidiary of CASI Phar­ma­ceu­ti­cals, Inc. head­quar­tered in Rockville, Mary­land.

Zhang possesses over 20 years of ex­ec­u­tive ex­pe­ri­ence in com­mer­cial op­er­a­tions, reg­u­la­tory af­fairs, sales and mar­ket­ing, and busi­ness de­vel­op­ment within the health­care and bio­phar­ma­ceu­ti­cal in­dus­tries in the U.S., Asia Pa­cific and China. Prior to join­ing CASI’s Bei­jing of­fice, Zhang was Vice Pres­i­dent, Head of Pub­lic Af­fairs and Cor­po­rate Re­spon­si­bil­ity at No­var­tis Group (China) fo­cus­ing on the pub­lic af­fairs and pub­lic re­la­tions strat­egy in­clud­ing ini­ti­at­ing No­var­tis’ China pol­icy fo­cus­ing on China FDA (CFDA) new drug ap­proval re­form, IP pro­tec­tion, generic qual­ity con­sis­tency eval­u­a­tion and new reg­u­la­tions on biosim­i­lars. In this role, he reg­u­larly li­aised with key cen­tral and pro­vi­sional gov­ern­ment au­thor­i­ties to ad­vance var­i­ous pol­icy initiatives.

Prior to join­ing No­var­tis Group (China), he served as Chief Ex­ec­u­tive Of­fi­cer of San­doz (China) Phar­ma­ceu­ti­cal Co. Ltd, a No­var­tis Com­pany, where he over­saw the suc­cess­ful launch of six new prod­ucts.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.